m.Stock by Mirae AssetOpen Demat Account
Molbio Diagnostics IPO

Molbio Diagnostics IPO: issue date, Lot size, price, everything you need to know

Molbio Diagnostics is a leading point-of-care diagnostics company focused on rapid, accurate testing for infectious and non-communicable diseases. Its IPO is a mix of a fresh issue and offer for sale, with proceeds from the fresh issue aimed at expanding R&D and manufacturing capabilities, while existing shareholders partially monetise their stake. 

Molbio Diagnostics is set to launch a ₹940 crore IPO, combining a fresh issue of ₹200 crore and an offer for sale (OFS) of 91.66 lakh shares. While the fresh issue proceeds will go toward strengthening the company’s R&D, manufacturing, and operational capabilities, the OFS portion will allow existing shareholders to partially monetise their stake, making this a mix of growth capital and shareholder exit. 

This guide covers the key details retail investors and business readers usually want: IPO dates, price band, structure, company profile, financials, sector context, and the main strengths and risks. 

Molbio Diagnostics IPO Dates & Launch Details

  • IPO opening date: 10th August 2026.
  • IPO closing date: 12th August 2026.
  • Basis of allotment: 13th August 2026.
  • Refund initiation / demat credit: 14th August 2026.
  • Expected listing date: 17th August 2026 (BSE & NSE). 

Price Band & Investment Details

  • Price band: ₹768 – ₹807 per equity share (face value: ₹1 per share).
  • Minimum lot size: 18 shares.
  • Minimum investment: ₹14,526 at the upper price band for retail investors.
  • Reservation: QIB up to 50%, NII 15%, retail 35%.
  • Lead managers: Kotak Mahindra Capital, IIFL Capital Services, and Jefferies India.
  • Registrar: KFin Technologies Ltd. 

IPO Structure

Detail 

Information 

Issue Type 

Fresh Issue & Offer for Sale (OFS) 

Issue Size 

₹939.70 crore 

Fresh Issue 

₹200 crore 

Offer for Sale 

91.66 lakh shares 

Promoters 

Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Exxora Trading LLP 

Reservations 

QIB: up to 50%, NII: 15%, Retail: 35% 

Listing Exchanges 

BSE, NSE 

Registrar 

KFin Technologies 

Lead Managers 

Kotak Mahindra Capital, IIFL Capital Services, Jefferies India 

The fresh issue proceeds are intended mainly for an R&D facility, a Centre of Excellence, connected office space, and new plant and machinery across Goa and Visakhapatnam units. 

About Molbio Diagnostics

Molbio Diagnostics is a Goa-based point-of-care molecular diagnostics company built around its proprietary Truenat platform, a portable PCR system designed for decentralised healthcare settings. The platform supports testing for 30 diseases through 42 assays, including TB, COVID-19, hepatitis, HIV, and HPV, and is used across more than 80 countries. 

The company operates multiple manufacturing facilities in India, including units in Goa, Visakhapatnam, and Bengaluru, and it generates revenue from both device sales and recurring test-kit sales. Its Truenat TB chip is one of the few WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection. 

Molbio Diagnostics Financials (₹ crore)

Period Revenue from Operations Net Profit Cash Flow from Operations Free Cash Flow 

FY26 

1,445.7 

164.1 

50.4 

0.8 

FY25 

1,020.4 

138.6 

287.1 

232.5 

FY24 

836.6 

83.5 

9.6 

-6.5 

 

Molbio has shown strong improvement in profitability and operating performance over the last three years. Revenue rose sharply from FY24 to FY26, EBITDA margins improved, and the company moved to solid profit in FY25 and FY26. 

Sector & Market Context

The diagnostics industry benefits from rising awareness, decentralised testing, and demand for faster point-of-care solutions. Molbio’s positioning is attractive because its products serve low-resource and high-volume healthcare settings, where speed, portability, and accuracy matter most. 

The business also has strong entry barriers: years of R&D, approvals, patent protection in over 100 countries, and a differentiated product platform that is already deployed across many markets. That said, it faces risks from regulatory dependence, competitive innovation, execution on international expansion, and the challenge of maintaining growth in a specialised segment. 

Key Considerations for Investors

Strengths

  • Differentiated diagnostics platform with global recognition and WHO-endorsed TB testing.
  • Strong revenue and profit growth trend over FY23–FY25.
  • Asset-light recurring opportunity from test kits, in addition to device sales.
  • Fresh issue proceeds support future capacity, R&D, and product development. 

Risks

  • The issue has a meaningful OFS component, so a large share of proceeds goes to selling shareholders rather than the business.
  • Diagnostics is a highly regulated space, and product adoption depends on approvals, pricing, and reimbursement dynamics.
  • The company’s growth depends on continued execution in new geographies and product categories. 

Opportunities

  • Increasing demand for decentralised and rapid diagnostics across India and overseas.
  • Expansion of the product portfolio beyond TB into broader infectious and non-communicable disease testing.
  • Higher installed base can support more recurring consumables revenue over time.  

Conclusion

Molbio Diagnostics’ IPO offers investors exposure to a high-quality diagnostics platform with proven technology, strong international reach, and improving financial performance. The valuation, issue mix, and OFS component should be weighed against the company’s growth runway, product differentiation, and the long-term opportunity in point-of-care healthcare diagnostics. 

More Related Articles

IFL Finance IPO

IFL Finance IPO

Calendar graphicNovember 13, 2026 | 0 mins read

IFL Finance Limited has moved from its earlier housing-finance identity towards a focused secured-lending model, with gold loans becoming the centre of its loan book. Its proposed IPO is therefore less about funding a new physical asset and more about adding capital to a balance sheet that is already scaling. The key questions are how durable the gold-loan growth can be, whether asset quality remains controlled as the book expands, and how efficiently the company can convert fresh Tier-I capital into profitable lending.

Read More
Bvishal Oil and Energy IPO

Bvishal Oil and Energy IPO

Calendar graphicNovember 13, 2026 | 0 mins read

Bvishal Oil and Energy Limited is a technology-driven onshore oilfield services provider serving the exploration, production and maintenance requirements of oil and gas wells. Its portfolio spans Well Intervention and Well Stimulation, Surface Production Testing and Gas Processing, Operations and Maintenance (O&M), Production Enhancement Services (PES) and Enhanced Oil Recovery (EOR). The company operates primarily in upstream and selected midstream activities rather than owning oil or gas reserves itself.

Read More
Master Chains N Jewels IPO

Master Chains N Jewels IPO

Calendar graphicNovember 13, 2026 | 0 mins read

Master Chains N Jewels is a Mumbai-based B2B gold jewellery manufacturer and wholesaler. It designs and manufactures gold chains and a wider range of lightweight jewellery, while also undertaking job-work and customised manufacturing for wholesalers, single-store retailers and multi-store jewellery chains.

Read More
View All

FAQ

The IPO opens on 10th August 2026 and closes on 12th August 2026, with listing expected on 17th August 2026. The issue size is about ₹939.70 crore, including a ₹200 crore fresh issue and 91.66 lakh shares via OFS.